J. J. Skydel

US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018

J. Wallach, J. Ross, S. Dhruva, 2021, Clinical trials.

US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018

J. Wallach, J. Ross, S. Dhruva, 2020, medRxiv.

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments

J. Wallach, J. Ross, S. Dhruva, 2019, JAMA network open.

Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study

P. Lurie, J. Wallach, J. Ross, 2022, BMJ.

Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019.

J. Wallach, J. Ross, S. Dhruva, 2020, JAMA internal medicine.

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017

J. Wallach, J. J. Skydel, Reshma Ramachandran, 2022, JAMA health forum.